Major Histocompatibility Complex class II pathway (MHC II pathway)

The Major Histocompatibility Complex class II (MHC II) pathway is a complex biological process essential for the adaptive immune system, primarily responsible for presenting exogenous antigens to CD4+ T helper cells (StatPearls, 2023). This pathway is predominantly active in professional antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. It involves the internalization of extracellular pathogens or proteins, their proteolytic cleavage into peptides within endolysosomal compartments, and the subsequent loading of these peptides onto MHC II heterodimers (e.g., HLA-DR, HLA-DQ) with the assistance of the chaperone HLA-DM (UniProt, P01903). Dysregulation of this pathway is a hallmark of autoimmune diseases like rheumatoid arthritis and multiple sclerosis, where self-antigens are inappropriately presented, as well as in oncology, where many tumors downregulate MHC II components to escape T-cell recognition (PubMed, PMC6527534). While the pathway itself is a multi-step process rather than a single protein target, specific components such as Cathepsin S and CIITA are actively pursued as therapeutic nodes to modulate immune responses in inflammatory and malignant conditions.

Other names

Antigen presentation via MHC class IIExogenous antigen presentation pathwayMHCII processing and presentationHLA class II pathway

Modulation of the pathway occurs through the inhibition of endosomal proteases like Cathepsin S to prevent invariant chain degradation, the induction of MHC II expression via the Class II Transactivator (CIITA) by Interferon-gamma, or the direct blockade of MHC II molecules using monoclonal antibodies.